Listen instead
A continuous stream of biometric signals
Five million users wear a lightweight titanium ring to bed every night, providing a continuous stream of biometric data that forms the foundation of Oura Health's transition to the public markets. For a median of 23 hours a day, these devices monitor resting heart rate, skin temperature, and sleep cycles. The continuous wear has allowed Oura to compile 42 billion hours of biometric data, a repository the company describes in its regulatory filings as one of the largest longitudinal biometric datasets in consumer health.
On September 3, 2026, the company moved to convert this dataset and its hardware business into a public listing, filing its Form S-1 with the Securities and Exchange Commission to list on the Nasdaq under the ticker OURA. The transition from a consumer hardware business to a data platform represents a significant test of how public market investors value consumer health wearables.
Inside the S-1 financial performance
The financial disclosures within the registration statement show a business that has achieved significant scale. For the nine months ended June 30, 2026, Oura reported revenue of $1.21 billion, which represents a 74 percent increase compared to the same period in the prior year. This builds on the performance of fiscal year 2025, during which full-year revenue reached $907.9 million, an increase of 123 percent from fiscal year 2024.
The operational efficiency of the business is visible in its margins and profitability. Gross margins for the nine months ended June 30, 2026, reached 55 percent, and the company recorded a net income of $60.8 million, up from $1.6 million during the prior year period. While the filing displays a headline net loss of $924.3 million, this figure reflects a deemed dividend accounting entry on preferred stock rather than actual operating losses.
Under the leadership of Chief Executive Officer Tom Hale, the business has transitioned to a subscription model, counting 5.0 million paid members as of June 30, 2026. This subscription model provides predictable recurring revenue, which is a key metric for public market software companies, even though Oura remains anchored in physical hardware sales.
Clinical positioning and strategic assets
The filing reveals details about the demographic makeup of Oura's base and its corporate partnerships. Women account for 72 percent of the paid membership, a distribution that sets Oura apart from many early stage wearable platforms that have historically attracted a predominantly male demographic. Furthermore, 37 percent of members have a household income below $100,000, indicating that the device has expanded beyond an affluent niche market.
Perhaps the most notable clinical connection disclosed is a Simple Agreement for Future Equity held by Eli Lilly. According to the filing, this agreement will convert directly into common stock upon the completion of the public listing. This relationship underscores how life sciences companies view the value of continuous, passive biometric monitoring in drug development and patient monitoring. To process and leverage its 42 billion hours of longitudinal data, Oura has integrated artificial intelligence capabilities. Its software stack relies on foundational models from OpenAI, Anthropic, and Google.
Establishing a defensive moat
While consumer hardware markets are historically vulnerable to rapid commoditization and low cost competitors, Oura has built a protective legal and intellectual property barrier. The company holds more than 1,140 patents. It has actively used these patents to enforce its market position, successfully blocking rivals such as Ultrahuman and RingConn from entering the United States market through actions at the International Trade Commission. This enforcement capability protects its domestic market share and high gross margins as it prepares for the public markets.
The public offering is being led by major Wall Street institutions, with Goldman Sachs, Morgan Stanley, and J.P. Morgan serving as the lead underwriters. Reports from Bloomberg indicate the offering could raise as much as $3 billion, valuing the company at more than $16 billion.
From a sector perspective, Oura's filing suggests that the consumer wearable category is evolving. It is no longer just about selling devices, but about building long-term, recurring relationships with users and licensing the resulting data to clinical partners. The success of the listing will depend on whether investors view Oura as a hardware company with hardware margins, or a clinical data platform with SaaS economics.
Source: The HealthTech Signal
